Objective: To disclose a novel mutation of the presenilin 1 (PS1) gene responsible for early-onset Alzheimer disease and to clarify genotype-phenotype correlation that should help to establish the function of this protein.
T
HE MAJORITY of known pedigrees of early-onset familial Alzheimer disease (AD) are linked to mutations in the presenilin 1 (PS1) gene on chromosome 14 . 1 At present, 47 missense mutations at 36 different codons and a point mutation upstream of a splice acceptor site that results in an in-frame deletion have been described in the PS1 gene in patients with early-onset AD. 2, 3 A further autosomal dominant locus for familial AD in Volga German kindreds was demonstrated on chromosome 1, 4, 5 and the responsible gene is now called the presenilin 2 (PS2) gene. PS1 and PS2 share overall amino acid sequence identity of 63%. 4, 5 The presenilins also share substantial sequence homologies with the Caenorhabditis elegans SEL-12. 6 In addition, a recent study showed that both PS1 and PS2 can functionally replace C elegans SEL-12, confirming that SEL-12 is a bona fide presenilin. 7 Protein topology studies of PS1 and SEL-12 confirmed that presenilins are integral membrane proteins with 6 to 8 transmembrane domains. 8, 9 Most PS1 mutations documented so far occur at residues that are conserved in the presenilin family. All presently known mutations of PS1 and PS2 are in nucleotides coding for amino acids that are conserved between the 2 presenilins, suggesting a functional significance of these residues.
We report in the present study the detection of a novel mutation, which is predicted to cause a missense substitution at codon 123 in the first hydrophilic loop of PS1 in a pedigree with earlyonset AD of Japanese origin. This mutation is the first to be identified at a residue that is not conserved in PS2. The 2 patients of this pedigree shared a dementia syndrome compatible with AD. These results provide evidence that a missense mutation at an amino acid that is not conserved between PS1 and PS2 can cause AD.
RESULTS

ABCD-2 FAMILY
The members of ABCD-2 family are Japanese ( Figure 1 ). There are no known links between this pedigree and other Japa-ORIGINAL CONTRIBUTION nese pedigrees associated with PS1 mutations. Clinical, neuroradiological, and neurophysiological examinations of the proband and his affected brother were consistent with the diagnosis of probable AD. 17 The proband had an apolipoprotein E ⑀3/⑀3 genotype, and his brother had an apolipoprotein E ⑀2/⑀3 genotype.
MUTATION ANALYSIS
The nucleotide and exon numberings described herein are in accordance with those of GenBank No. L76518-76528. Complete sequencing of the PS1 gene of the proband (III-2) in family ABCD-2 disclosed a new missense mutation (G to A) in 1 allele at nucleotide 615 in exon 6, which is predicted to cause a glutamic acid-to-lysine missense substitution at codon 123 (E123K) in the first hydrophilic loop of PS1. The substitution of G to A abolishes the restriction site for Alw26I (Figure 2) . The polymerase chain reaction-restriction fragment length polymorphism analysis confirmed the heterozygote substitution at nucleotide 615 of the PS1 gene. The same substitution was found in the DNA of the affected brother (III-1) but was not found in 100 healthy control subjects or in 104 patients with sporadic AD.
PATIENTS AND METHODS
PROBAND
The pedigree designated as ABCD-2 family was ascertained through the Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan. All investigations were performed with the written informed consent of participating family members or next of kin.
The proband (Figure 1) , a 57-year-old factory worker, was admitted to the hospital of the Hyogo Institute for Aging Brain and Cognitive Disorders with a 1-year history of progressive memory problems and personality changes. He showed severe amnesia, disorientation in time and place, and word-finding difficulty, but his visuospatial ability was preserved. Magnetic resonance imaging showed severe atrophy in the bilateral medial temporal lobes and moderate atrophy in the bilateral parietal lobes. Positron emission tomography demonstrated hypoperfusion in the bilateral temporal and parietal lobes.
AFFECTED FAMILY MEMBERS
The elder brother of the proband, a 65-year-old security guard, was admitted to the hospital of Hyogo Institute for Aging Brain and Cognitive Disorders for examination with a 3-year history of progressive memory problems and speech impediment. He was disoriented in time and place and his memory for recent events was very poor. He showed a marked word-finding difficulty and his arithmetic skills were poor, but his ability to copy a complex figure was well preserved. Magnetic resonance imaging demonstrated that diffuse cerebral cortical atrophy was more marked in the bilateral medial temporal lobes. Positron emission tomography showed biparietal, bitemporal, and bifrontal hypoperfusion.
The proband and his brother had the same mother and father. The mother died of peritonitis at the age of 33 years. The father remarried and had 2 more children, who were not affected (ages 52 and 50 years). The father remained healthy without any cognitive decline until he died at the age of 80 years. The mother of the proband had 5 siblings, 3 of whom (cases II-4, II-5, and II-6) died young of pneumonitis, war, and measles, respectively, and showed no signs of dementia. However, 1 of her brothers (case II-3) and her father had had neuropsychiatric disorders of unknown types and died at 56 and 65 years of age, respectively, several years after the onset. Therefore, the mutant allele may have been inherited from the proband's maternal grandfather.
NEUROPSYCHOLOGICAL ASSESSMENT
Family members were investigated with a battery of tests to measure intellectual, language, visuospatial, executive, and memory abilities, and to ascertain their general level of cognitive functioning. The assessments were performed while the subjects were free of neuroleptic and neurotropic agents and not in an episode of confusion. The battery included the Wechsler Adult Intelligence Scale-Revised, 10 Western Aphasia Battery, 11 Wechsler Memory Scale-Revised, 12 Alzheimer's Disease Assessment Scale-Cognitive subscale, 13 and the Mini-Mental State Examination.
14 In addition to the total score of the Mini-Mental State Examination, Alzheimer's Disease Assessment Scale-Cognitive subscale, Western Aphasia Battery (aphasia quotient), and Wechsler Adult Intelligence ScaleRevised (full-scale IQ, verbal IQ, and performance IQ) were separately analyzed. Orientation was assessed by using the temporal and locational orientation subtests of the MiniMental State Examination.
14 The Alzheimer's Disease Assessment Scale-Cognitive subscale recall subtest is inherent in a verbal learning test, in which the registration of a list of 10 written high-imagery words was measured by free immediate recall after each of 3 learning trials. The recall score was expressed as the mean number of words not recalled in 3 trials. The Alzheimer's Disease Assessment Scale-Cognitive subscale total score was analyzed as another index of severity of dementia in terms of overall cognitive impairment.
MOLECULAR GENETIC STUDIES
Genomic DNA was extracted from peripheral leukocytes as described previously. 15 The target PS1 gene was amplified by the polymerase chain reaction with the use of primers derived from intronic sequences as described previously. 16 The amplified DNA was ligated with the vector pCR2.1 (Original TA Cloning kit; Invitrogen Corp, Carlsbad, Calif) according to the manufacturer's protocol. Plasmid DNA from 5 positive clones wasisolatedandpurifiedbythealkaline-lysismini-prepmethod (AIA tip-20 kit; Qiagen, Hilden, Germany), and completely sequenced (both alleles) by applying the T7 autoread sequencing protocol (Pharmacia, Uppsala, Sweden). The M13 (−40) forward and reverse primers were used for sequencing clones containing fragment inserts of the target genes. Sequencing was performed electrophoretically with the Alfred Sequencer apparatus (Pharmacia). Mutations were identified by comparison of sequences with GenBank sequence data (National Center for Biotechnology Information, Bethesda, Md; available at: http://www.ncbi.nlm.nih.gov/). In addition, we screened 100 controls and 104 patients with late-onset AD for the presence of the mutation by restriction fragment length polymorphism.
EARLY CLINICAL PHENOTYPE ASSOCIATED WITH THE PS1 CODON 123 MUTATION
The initial prospective neuropsychological assessment of subject III-2 at symptom year 3 showed deficits in several measures of memory, in executive abilities concerning cognitive processing speed, and in attention to complex cognitive sets ( Table 1) . Reevaluation with the same protocols at symptom year 4 showed both the persistence of these deficits and the acquisition of deficits in concept formation. Neither subject showed deficits in nonmemory language and visuospatial functions. Patient III-1 shared a common phenotype with patient II-2 (Table 1) .
COMMENT
In the present study, we described a novel E123K mutation in the PS1 gene of 2 patients in the ABCD-2 family with early-onset AD. The E123K mutation is of particular interest, because it alters a residue that is not conserved in PS2. Although PS1 and PS2 share 63% overall amino acid sequence identity, several domains show almost complete identity, especially in the putative transmembrane domains, 4, 5 where the vast majority of mutations are clustered (Figure 3) . Even in the hydrophilic loops, where there is a great sequence divergence in the amino acid sequence between PS1 and PS2, known mutations in PS1 have all occurred at residues that are conserved in PS2. Thus, so far all 36 of the affected residues in PS1 are conserved in PS2. The E123K mutation of the ABCD-2 family is the first to be identified at a residue that is not conserved in PS2. Although any base pair of DNA may be mutated, the residues that are conserved between the presenilins have far more AD-associated mutations than would be expected from a random distribution, which indicates essential functions for the conserved residues. Since PS1 and PS2 appear to be similar in their ability to substitute for SEL-12, they may also have overlapping functions in mammals. 7 Recently, a PS1 mutation associated with early-onset AD was described at a site homologous to a PS2 mutation in Volga German kindreds, indicating that the alteration of a common residue can cause AD. 18 Therefore, it is likely that the common residues between PS1 and PS2 are important for presenilin function associated with AD. On the contrary, the missense mutations that occur at the nonconserved residues might be expected to be functionally silent, ie, they might be so-called neutral substitutions. However, this possibility seems unlikely, because no substitutions were found in PS1 in individuals who did not have early-onset AD (either controls or patients with lateonset sporadic AD). 19 The site of the E123K mutation is also located at an amino acid residue that is conserved in the PS1 of mice and rats, but not in SEL-12. The similarity of murine and Alw26I restriction enzyme analysis of the nucleotide 615 (G to A) mutation. The amplification primers (forward, the 2057 primer; reverse, the 911 primer) and polymerase chain reaction conditions were as previously described. 16 The normal polymerase chain reaction product was 260 base pairs (bp), which was cleaved to 122-, 93-, and 45-bp fragments after Alw26I digestion. The proband and his brother were heterozygous for a G to A transition that abolishes a restriction enzyme site. When the amplified mutant fragment was digested with Alw26I and resolved on a 10% nondenaturing polyacrylamide gel, a novel band at 215 bp appeared. human PS1 amino acid sequences is about 92%. 1, 20 All of the affected residues are conserved in the murine sequence with the exception of a German patient with earlyonset AD with the E318G mutation. 21 The C elegans SEL-12 gene product displays about 50% amino acid sequence identity to PS1 and PS2. 6 Eighty-one percent (29/ 36) of the affected residues in PS1 are conserved in SEL-12. Therefore, the mutations preferentially occur at residues that are strictly conserved through evolution. The characteristics of PS1 mutations that occur at residues that are not conserved among the presenilin family are listed in Table 2 . Seven PS1 mutations that have been identified in patients with early-onset AD occur in residues that are not conserved in SEL-12. These patients had ages at onset that ranged from 32 to 55 years. This range extensively overlaps with the age at onsets in the pedigrees having early-onset AD in which the affected residues in PS1 are ones that are conserved in SEL-12. A patient with a mutation (E318G) occurring at an amino acid residue that is not conserved in the murine sequence had Figure 3 . Schematic representation of transmembrane structure of the presenilin 1 protein, modified from Doan et al, 8 and its amino acid sequence. The mutated amino acid residues that are so far known are described by white letters. The arrow indicates the glutamic acid (E)-to-lysine (K) missense substitution at codon 123 of the ABCD-2 family in this study. Amino acid residues that are not conserved between human PS1 and PS2 are indicated by an asterisk. All of the PS1 mutations that are so far known have occurred at residues that are conserved in PS2. 
